Design Therapeutics, Inc. — Director's Dealing 2021

Mar 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Design Therapeutics, Inc. (DSGN)
CIK: 0001807120
Period of Report: 2021-03-25

Reporting Person: Schmid John P. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-25	Stock Option (right to buy)	$20.00	A	15000	Acquired	2031-03-24	Common Stock (15000)	Direct

Footnotes

F1: The shares subject to the option vest in equal monthly installments over the 12 months following March 25, 2021.